Mannin Research is developing therapeutics for vascular diseases. High intraocular eye pressure (IOP) is one of the main causes of glaucoma. Using their proprietary research platform, Mannin is developing a unique molecule that can be administered via eye drops to reduce IOP. This lead indication is being tested for treatment of primary open-angle glaucoma. In addition, Mannin is researching therapeutics that could treat cystic kidney disease, pediatric glaucoma and inflammation. This will enable Mannin to establish a deep pipeline of novel therapeutics.

Mannin Research

Founded: 2012
Location: Toronto, ON
Employee range: 1 - 10
Clinical stage: Clin0
Therapy area: Glaucoma
Drug types: OPH, NPH
Lead product: Man-01
Funding: 10-100M

Drug notes:

About:

Jobs: